$RGBP premarket news out! Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc. http://finance.yahoo.com/news/regen-biopharma-inc-licenses-nr2f6-130000603.html